Johnson & Johnson $JNJ Shares Sold by ProShare Advisors LLC

ProShare Advisors LLC decreased its holdings in Johnson & Johnson (NYSE:JNJ) by 5.6% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,131,562 shares of the company’s stock after selling 66,943 shares during the quarter. Johnson & Johnson accounts for approximately 0.4% of ProShare Advisors LLC’s holdings, making the stock its 29th biggest position. ProShare Advisors LLC’s holdings in Johnson & Johnson were worth $299,570,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Vise Technologies Inc. raised its holdings in Johnson & Johnson by 30.2% in the 3rd quarter. Vise Technologies Inc. now owns 275,901 shares of the company’s stock worth $73,042,000 after purchasing an additional 64,038 shares during the period. Investment Partners LTD. lifted its holdings in shares of Johnson & Johnson by 115.0% in the third quarter. Investment Partners LTD. now owns 10,462 shares of the company’s stock worth $2,770,000 after buying an additional 5,595 shares in the last quarter. Blue Fin Capital Inc. boosted its holdings in shares of Johnson & Johnson by 0.6% during the 3rd quarter. Blue Fin Capital Inc. now owns 20,828 shares of the company’s stock valued at $5,514,000 after purchasing an additional 118 shares during the last quarter. Summit Global Investments boosted its stake in Johnson & Johnson by 61.5% during the third quarter. Summit Global Investments now owns 15,838 shares of the company’s stock valued at $4,193,000 after buying an additional 6,030 shares during the last quarter. Finally, MGO One Seven LLC boosted its position in shares of Johnson & Johnson by 3.5% during the 3rd quarter. MGO One Seven LLC now owns 126,490 shares of the company’s stock valued at $33,487,000 after acquiring an additional 4,303 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the stock. Royal Bank Of Canada lowered their price target on shares of Johnson & Johnson from $290.00 to $280.00 and set an “outperform” rating for the company in a report on Wednesday, October 14th. JPMorgan Chase & Co. upped their price target on shares of Johnson & Johnson from $270.00 to $285.00 and gave the stock a “neutral” rating in a report on Tuesday, September 29th. Wells Fargo & Company raised their price objective on Johnson & Johnson from $275.00 to $287.00 and gave the stock an “overweight” rating in a report on Friday, October 16th. Sanford C. Bernstein set a $270.00 target price on shares of Johnson & Johnson in a research report on Thursday, October 15th. Finally, Erste Group Bank lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, October 21st. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $275.92.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: New real-world and observational analyses presented at the TCT 2026 symposium found lower in-hospital and short-term mortality among high-risk percutaneous coronary intervention patients supported by Impella pumps. The findings covered 1,379 patients in U.S. and European hospitals and compared favorably with results from the CHIP-BCIS3 study. Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI
• Positive Sentiment: A separate report cited a 94% success rate in a coronary-device trial, adding to evidence that Impella could improve outcomes in complex coronary procedures. Stronger clinical support could help J&J expand adoption of the devices and reinforce its medical-technology growth strategy. Johnson & Johnson reports 94% success rate in trial of coronary artery device
• Positive Sentiment: Clinicians also reviewed progress in the ongoing PROTECT IV trial, which is expected to provide additional evidence for Impella-supported high-risk procedures. Further positive results could improve confidence in the product’s long-term commercial potential. What Is Johnson & Johnson Signaling With Its New Impella Heart Pump Data?
• Neutral Sentiment: Exchange-traded funds purchased approximately $35.1 million of JNJ shares on October 29, suggesting institutional demand, though the transaction alone does not establish a lasting change in investor sentiment. ETFs Are Buying Johnson & Johnson
• Negative Sentiment: Some coverage questioned whether JNJ is fully valued after strong recent performance, including a reported 6.71% 30-day return and 31.76% year-to-date gain. That raises the risk that positive Impella news is already reflected in the stock and could limit near-term upside. Johnson & Johnson As Impella Data Fuels The Story, Is The Stock Fully Valued?

Johnson & Johnson Trading Down 0.9%

NYSE JNJ opened at $270.81 on Tuesday. The company has a fifty day simple moving average of $265.74 and a two-hundred day simple moving average of $247.22. Johnson & Johnson has a 12-month low of $185.12 and a 12-month high of $282.02. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44. The stock has a market cap of $651.93 billion, a P/E ratio of 41.03, a P/E/G ratio of 2.68 and a beta of 0.21.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.06. The business had revenue of $25.40 billion for the quarter, compared to the consensus estimate of $25.38 billion. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The company’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, analysts forecast that Johnson & Johnson will post 11.12 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be issued a $1.34 dividend. This represents a $5.36 annualized dividend and a yield of 2.0%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio is presently 81.21%.

Insider Transactions at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 15,000 shares of the firm’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the sale, the executive vice president owned 194,451 shares in the company, valued at approximately $51,210,615.36. This trade represents a 7.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the sale, the executive vice president owned 25,447 shares in the company, valued at $6,991,308.78. This trade represents a 56.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 64,515 shares of company stock worth $17,271,766 over the last quarter. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Company Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.